A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS EFZOFITIMOD IN PATIENTS WITH PULMONARY SARCOIDOSIS

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506039-13-00

Acronym

ATYR1923-C-004

Enrollment

101

Registered

2023-07-10

Start date

2023-04-12

Completion date

2025-07-10

Last updated

2025-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary sarcoidosis

Brief summary

Change from baseline in mean daily OCS dose at Week 48

Detailed description

1. Steroid-free rate at Week 48, 2. Steroid-free and stable KSQ-Lung composite rate at Week 48, 3. Change from baseline in absolute value of FVC at Week 48

Interventions

DRUG-

DRUGEfzofitimod

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline in mean daily OCS dose at Week 48	—

Secondary

Measure	Time frame
1. Steroid-free rate at Week 48, 2. Steroid-free and stable KSQ-Lung composite rate at Week 48, 3. Change from baseline in absolute value of FVC at Week 48	—

Countries

France, Germany, Italy, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026